Oliver Sartor, MD, of Mayo Clinic, discusses the phase III PSMAfore trial, which analyzed the use of 177Lu-PSMA-617 against an alternative androgen receptor pathway inhibitor – either abiraterone or enzalutamide – in taxane-naive patients with metastatic castration-resistant prostate cancer. Dr. Sartor offers insight on the efficacy of 177Lu-PSMA-617 in prolonging progression-free survival rates, and the associated low risk of grade 3-4 adverse events. While he notes that there is still more to learn regarding patient dosing and scheduling, the trial researchers hope to gain an FDA approval for the treatment to benefit patients who may ...
RLT
Advertisement
Latest News
The panel discusses the emerging field of PSMA-targeted alpha radioligand therapy, with a focus on HK2.
The panel discusses the results of PEACE-3, which evaluated enzalutamide with or without radium-223 for MCRPC.
The panel discusses two significant trials in metastatic hormone-sensitive prostate cancer.
Part 2 of the Radioligands session from Uromigos Live 2024 features a discussion on the SPLASH results from ESMO 2024.
The first part of five segments from the Uromigos Live 2024 session on radioligands.
Early phase I data on 177Lu rhPSMA-10.1 has demonstrated an encouraging safety profile for the novel radioligand therapy.
Advertisement
Expert Interviews
Prostate Cancer Knowledge Hubs
Curated clinical content on prostate cancer types, therapies, and technologies
Conference Coverage
Dr. Shuch shares the key points from his presentation on advancements in molecular imaging for RCC from SUO 2024.
Dr. Daneshmand discusses the impressive complete response rate and durability of TAR-200 monotherapy for NMIBC.
In the PENELOPE study, TAR-200 showed greater tissue penetration of gemcitabine compared to standard intravesical therapy.
The panelists share their insights on risk assessment, and customized treatment strategies for high-risk NMIBC.
The panelists discuss the evolving landscape of bladder cancer treatments, focusing on balancing bladder-sparing therapies.
The panelists debate the potential of combining intravesical immunotherapy with immune checkpoint inhibitors.
Advertisement
Section Editor
Advertisement
Roundtables
The panel discusses lutetium-177-PSMA for the treatment of advanced prostate cancer and reviews the VISION trial.
Panel experts discuss PSMA-targeting agents currently being assessed, including PSMA-I&T-Lutetium-177.
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.